A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular PCV
Phase of Trial: Phase IV
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Verteporfin (Primary) ; Ranibizumab
- Indications Choroid diseases
- Focus Therapeutic Use
- Acronyms EVEREST II
- Sponsors Novartis
- 02 May 2017 Status changed from active, no longer recruiting to completed.
- 13 Feb 2017 Planned End Date changed from 1 Apr 2017 to 7 Mar 2017.
- 13 Feb 2017 Planned primary completion date changed from 1 Apr 2017 to 7 Mar 2017.